Isolated hypercalciuria with mutation in CLCN5: Relevance to idiopathic hypercalciuria  by Scheinman, Steven J. et al.
Kidney International, Vol. 57 (2000), pp. 232–239
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Isolated hypercalciuria with mutation in CLCN5:
Relevance to idiopathic hypercalciuria
STEVEN J. SCHEINMAN, JEREMY P.D. COX, SARAH E. LLOYD, SIMON H.S. PEARCE,
PAGE V. SALENGER, RICHARD R. HOOPES, DAVID A. BUSHINSKY, OLIVER WRONG,
JOHN R. ASPLIN, CRAIG B. LANGMAN, ANTHONY G.W. NORDEN, and RAJESH V. THAKKER
Department of Medicine, SUNY Health Science Center, Syracuse, New York, USA; MRC Molecular Endocrinology Group,
Hammersmith Hospital, London, England, United Kingdom; Department of Medicine, University of Rochester, Rochester, New
York, USA; Department of Nephrology, The Middlesex Hospital, London, England, United Kingdom; Department of Medicine,
University of Chicago, and Department of Pediatrics, Division of Nephrology and Mineral Metabolism, Northwestern University
Medical School and Children’s Memorial Hospital, Chicago, Illinois, USA; and Department of Chemical Pathology,
Chase Farm Hospital, Enfield, England, United Kingdom
Isolated hypercalciuria with mutation in CLCN5: Relevance In the United States, three men in a thousand will
to idiopathic hypercalciuria. experience a first kidney stone each year [1], and a posi-
Background. Idiopathic hypercalciuria (IH) is the most tive family history of kidney stones increases that risk
common risk factor for kidney stones and often has a genetic
twofold to threefold [2]. Seventy to 80% of stones containcomponent. Dent’s disease (X-linked nephrolithiasis) is associ-
calcium oxalate or calcium phosphate. Idiopathic hyper-ated with mutations in the CLCN5 chloride channel gene,
and low molecular weight (LMW) proteinuria was universally calciuria (IH), in which the blood calcium level is normal,
observed in affected males. We sought to identify mutations is the most common metabolic abnormality associated
in CLCN5 or abnormalities in LMW protein excretion in a with nephrolithiasis [3]. In many patients, a hereditary
large group of patients with IH and in a rat model of genetic component may be an important determinant of calciumhypercalciuria.
excretion. Forty to 45% of patients with IH have at leastMethods. One hundred and seven patients with IH (82 adults
one family member with nephrolithiasis [4, 5]. Apparentand 25 children) and one asymptomatic hypercalciuric man
with a known inactivating mutation in CLCN5 were studied. autosomal inheritance of hypercalciuria has been ob-
Secondary causes of hypercalciuria were excluded in all. The served in individual families [6–8], but it is likely that
excretion of retinol-binding protein and b2-microglobulin was multiple factors, possibly multiple genes, contribute to
measured by immunoassay in 101 patients with IH. Mutation
determining calcium excretion [9].analysis of the CLCN5 gene was performed in 32 patients with
In the disease X-linked nephrolithiasis, also known asIH and in the genetic hypercalciuric stone-forming (GHS) rat
Dent’s disease, calcium excretion is usually excessive instrain.
Results. LMW protein excretion was normal in 92 patients patients whose renal function is still normal. Affected
with IH, and only slight abnormalities were found in the other individuals have been found to have inactivating muta-
nine, none of whom had a mutation in CLCN5. One 27-year- tions in the CLCN5 gene on the X chromosome (Xp11.22)
old man who had a CLCN5 mutation was found to have isolated
that encodes a voltage-gated chloride channel ClC-5 thathypercalciuria without LMW proteinuria, renal failure, or other
is expressed predominantly in the kidney [10, 11]. Atevidence of renal disease. Mutation analysis was normal in 32
patients with IH. The CLCN5 sequence was normal in the the time of writing, 35 inactivating mutations in the
GHS rat. CLCN5 gene have been reported in 46 families [11–20].
Conclusions. Inactivation of CLCN5 can be found in the The disease associated with CLCN5 mutations encom-
setting of hypercalciuria without other features of X-linked passes several syndromes that are characterized by hyper-nephrolithiasis. However, mutations in CLCN5 do not repre-
calciuric nephrocalcinosis, calcium stone disease, renalsent a common cause of IH.
failure, and in some cases rickets, in addition to low
molecular weight (LMW) proteinuria [10, 17, 21, 22].
This latter feature, defined as abnormal urinary loss ofKey words: X-linked nephrolithiasis, Dent’s disease, low molecular
weight proteinuria, chloride channel, kidney stones. proteins smaller than 40 kd, is evidence of dysfunctional
proximal tubular solute reabsorption. The relative sever-Received for publication April 29, 1999
ity of these features can vary greatly among affectedand in revised form July 12, 1999
Accepted for publication July 19, 1999 males, even within families with a common mutation in
CLCN5 [10]. However, LMW proteinuria is the most 2000 by the International Society of Nephrology
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consistent abnormality in this disease. In all reports, ter at Syracuse and the Syracuse Veterans Administra-
LMW protein excretion was abnormal in extreme de- tion Hospital, the University of Chicago, the Middlesex
grees in all affected males in whom it was measured [12, Hospital in London, England, and the Bone and Mineral
14–20, 22–24]. Metabolism Program at the Department of Pediatrics
We identified a man with an inactivating mutation in of Northwestern University Medical School in Chicago.
CLCN5 who did not have LMW proteinuria and in whom Adults presented with nephrolithiasis, and children pre-
the only biochemical abnormality was hypercalciuria. This sented with either with kidney stones or hematuria. Stud-
raised the question of whether mutations in CLCN5 ies were approved by the Institutional Review Board for
might contribute to the phenotype in patients with the the Protection of Human Subjects at each institution,
diagnosis of IH, a condition that is twice as common in and informed consent was obtained. Ten of the adults
males as in females. Thus, we performed mutational and six of the children were female.
analysis of the CLCN5 gene in a group of stone-forming Idiopathic hypercalciuria was defined as hypercalci-
patients with IH, and we screened a larger number of uria in the absence of systemic disease or other secondary
patients with IH for LMW proteinuria, which is a sensi- explanation. We used this definition because it is more
tive marker for Dent’s disease [22, 23]. In a complemen- widely used than the restrictive definition occasionally
tary approach, we used an animal model, the genetic employed whereby IH is taken to refer only to patients
hypercalciuric stone-forming (GHS) rat, in which mecha- with “renal leak” of calcium and also because in Dent’s
nisms of hypercalciuria resemble those found in many disease, the mechanisms of hypercalciuria include both
humans with IH [25–27]. Because the CLCN5 gene is excessive intestinal absorption of dietary calcium and
expressed along the rat nephron [28, 29] and could con- fasting hypercalciuria [23]. Hypercalciuria was defined
tribute to hypercalciuria found in this animal model, we in adults as 24-hour urinary calcium excretion exceeding
analyzed the sequence for CLCN5 in the GHS rat. 250 mg in women or 300 mg in men or exceeding 4 mg/kg
body weight on multiple collections while ingesting an
unrestricted diet [31]. In children, the minimum criterionMETHODS
was a calcium excretion exceeding 3.5 mg/kg body weightPatient characteristics
on multiple collections [32]. Patients were excluded if they
X-linked recessive nephrolithiasis. One patient was had hyperparathyroidism, hypercalcemia, malignancy,
identified in a large pedigree, previously described, with immobilization, excessive vitamin ingestion, or evidence
X-linked recessive nephrolithiasis (XRN) [21]. This pa- for any endocrinologic disease or inflammatory process
tient had the same missense mutation (Gly506Glu) shared known to cause hypercalciuria. Because hypocitraturia,
by affected members of the family, but he lacked renal
hyperoxaluria, and hyperuricosuria often coexist with
stones, nephrocalcinosis, or renal failure and was not
hypercalciuria in patients with nephrolithiasis, and hyper-previously classified as affected. This patient (individual
uricosuria and can be seen in patients with Dent’s disease,V-4 in the report describing mapping of the gene [30])
patients were not excluded for the presence of any ofwas studied further, including measurement of LMW
these stone risk factors. Clinical data on the patientproteins, urinary calcium excretion, and renal ultrasonog-
groups are shown in Tables 1, 2, and 3.raphy. This 27-year-old man had an episode of dysuria
Normal individuals. Normal ranges for LMW proteinat the age of six years but otherwise has had no renal
excretion were established in 61 British adults aged 16.1colic, hematuria, or other symptoms to suggest kidney
to 58 years (32 males and 29 females) and 66 childrenstones and had no significant illnesses. Glomerular func-
aged 3 to 16 years (41 boys and 25 girls). None had ation was normal, with serum creatinine 5 1.1 mg/dL and
personal or family history of renal disease, and nonecreatinine clearance 5 114 mL/min; the renal ultrasono-
were taking nephrotoxic medications.gram was normal. Calcium excretion (the mean of three
collections) was 351 mg/24 hr (normal ,300 mg) and
Measurement of low molecular weight proteins in urine
total protein excretion was 133 mg/24 hr (normal ,150).
Urinary excretion of LMW proteins was measured inOn three separate occasions, the mean excretion of b2-
samples collected in sodium azide and stored at 2808C.microglobulin was 0.018 mg/mmol creatinine (normal
Retinol-binding protein was measured by solid-phase,0.052), and the excretion of retinol-binding protein
enzyme immunoassay, for which reference ranges have(RBP) was 0.008 mg/mmol creatinine (normal ,0.017).
been established for adults and children [33]. b2-micro-The urine tested negative for blood, and urinalysis was
globulin was measured by fluoroimmunoassay on thenormal. Thus, the only biochemical abnormality was
Abbott IMx analyzer (Abbott Diagnostics, Maidenhead,hypercalciuria.
UK) [23]. For comparison, data are also shown for af-Idiopathic hypercalciuria. Eighty-two adults and 25
fected males and obligate carrier females with X-linkedchildren with IH were identified from the Stone Clinics
at University Hospital of the SUNY Health Science Cen- nephrolithiasis/Dent’s disease, including a number of in-
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Table 1. Biochemical characteristics of the 82 adults with idiopathic hypercalciuria
Urine calcium
mg/24 hr Serum calcium Serum phosphorus PTHa 1,25(OH)2DAge
(range 22–75) Men Women mg/dL pg/mL
Mean 49.2 373 334 9.7 3.0 22.0 57.4
sd 12.9 88 55 0.5 0.6 6.1 27.7
N 82 72 10 78 71 12 8
a Only those PTH levels measured by the immunoradiometric (IRMA) assay are represented here; PTH measurements performed using a variety of other assays
were normal in another eight patients
Table 2. Biochemical characteristics of the 25 children with idiopathic hypercalciuria
Plasma ionized calcium Serum phosphorus PTHa 1,25(OH)2DAge Urine calcium
(range 5–18) mg/kg/24 hr mg/dL pg/mL
Mean 9.8 5.3 5.12 4.7 22.2 43.6
sd 3.6 1.7 0.18 0.7 10.4 26.7
N 25 25 20 25 23 22
a PTH measured by IRMA assay
Table 3. Clinical characteristics of subjects with of 24 subjects and direct sequencing in 17; in 9, both
idiopathic hypercalciuria
were performed; thus, the total number of subjects with
Adults Children IH screened for mutations was 32.
(N 5 82) (N 5 25) Mutational analysis of the rat CLCN5 gene was per-
Females 10 6 formed using RNA extracted from the kidney of a male
Hyperoxaluria 25 0
GHS rat in the 38th generation of inbreeding, and fromHyperuricosuria 17 0
Hypocitraturia 16 6 a normal rat, together with rat CLCN5-specific primers
Medullary sponge kidney 2 0 (details available on request) in RT-PCR reactions to
Gout 2 0
amplify the 2238 base pair coding region and exon–intronUrinary acidification defect 2 0
Family history of stones 35 9 boundaries [11].
Hyperoxaluria was defined as an oxalate excretion exceeding 40 mg/24 hr in
adults, and in children up to 15 years old, oxalate excretion exceeding 0.07
mmol/mol creatinine, or after 15 years old exceeding 0.04 mmol/mol creatinine; RESULTS
hyperuricosuria as uric acid excretion exceeding 750 mg in women or 800 mg/
day in men, or in children exceeding the 95% confidence intervals for age X-linked recessive nephrolithiasis (Dent’s disease)
established by Stapleton et al [47]; and hypocitraturia as citrate excretion below
550 mg/day in women or 450 mg/day in men, or in children under 9 years old One adult male (V-4) was identified with a very mild
citrate excretion below 0.27 mmol/mol creatinine or (after 9 years old) below
phenotype (isolated hypercalciuria) despite the presence0.20 mmol/mol creatinine. Acidification defect was defined as failure to reach a
urine pH below 5.5 on a first-morning urine specimen or with acid loading. of a missense mutation (Gly506Glu) that has been shown
to inactivate chloride currents [11]. Confirmation of the
presence of this mutation in patient V-4 is shown in
Figure 1. As illustrated for affected males V-1, IV-8, anddividuals previously reported [22, 23, 34] as well as new,
III-15, and as reported in other males in this family [11,unreported patients diagnosed recently.
21], this same mutation was associated with a severe
CLCN5 mutation analysis phenotype in other family members at the same age as
this patient, including recurrent nephrolithiasis and/orDNA sequence analysis of human CLCN5 was per-
renal failure (Fig. 1).formed using either genomic DNA or RNA obtained
from Epstein-Barr–transformed lymphoblasts and reverse
Idiopathic hypercalciuriatranscriptase-polymerase chain reaction (RT-PCR) as
This group comprised 107 patients (82 adults and 25described [11, 12]. Mutational detection by single-strand
children). Two adults were included who carried theconformational polymorphisms (SSCPs) was performed
radiographic diagnosis of medullary sponge kidney, aas we reported previously [13], and the presence of the
condition occasionally associated with hypercalciuria.Gly506Glu mutation previously documented in the large
No patient had a diagnosis of primary renal tubular aci-pedigree with XRN [21] was detected using appropriate
dosis, although two had some impairment in urinaryCLCN5-specific primers and Mnl1 restriction enzyme
analysis as described [11]. SSCP was performed in a total acidification that was probably secondary to hypercalci-
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Fig. 1. Identification of the Gly506Glu muta-
tion in selected members of the extended pedi-
gree previously reported with XRN. (A) The
mutation GGG→GAG in codon 506 is shown
and leads to substitution of glutamine for gly-
cine. The mutation creates a restriction endo-
nuclease recognition sequence for the enzyme
Mnl1, as indicated. (B) Selected members of
generations III, IV, and V of the previously
reported [30] extended pedigree with XRN are
represented. The presence or absence of LMW
proteinuria (upper right quadrant), hypercal-
ciuria (lower right quadrant), nephrolithiasis
or nephrocalcinosis (lower left quadrant), and
renal insufficiency (upper left quadrant) are
indicated in the patient symbols. Carrier fe-
males with a normal phenotype are indicated
by a dot within a circle, including a member
of generation II (II-4). The male with isolated
hypercalciuria is individual 4 in generation V.
Aligned below the pedigree is a photograph
of an agarose gel demonstrating detection of
the Gly506Glu mutation by restriction en-
zyme analysis as described by Lloyd et al [11].
Each patient symbol in the pedigree is aligned
above the lane in the gel representing the re-
striction digest for that patient, in addition to
three normal unrelated individuals (N1, N2,
and N3.) (C) Restriction map of the normal
[wild-type (WT)] and mutant (m) sequences
are shown indicating PCR primers (arrows)
and the Mnl1 digestion site. The WT sequence,
lacking the Mnl1 site, survives digestion at a
size of 129 bp, as in the three normal individu-
als (B). The mutant sequence is digested to
yield fragments of 48 and 81 bp, as occurs with
affected males V-1, V-4, IV-8, and III-15 in
the family (B). Carrier females (III-6, IV-3,
IV-5, and II-4) are heterozygous for WT and
mutant fragments.
uric renal damage, one of whom had nephrocalcinosis. 8 adults) and were in the upper quartile of the normal
range, as previously reported for children with IH (Ta-Thirty-five (41.7%) of the adult patients, and nine (36%)
of the children had a family history of kidney stones, a bles 1 and 2) [35].
Measurements of urinary excretion of LMW proteinsproportion that is very consistent with that reported in
other series of IH [4, 5]. were made in 101 patients with IH. Urinary excretion
of the LMW proteins RBP and b2-microglobulin areThe distribution of calcium excretion in the adults with
IH (373 6 88 mg/day, mean 6 sd) was indistinguishable shown in Figure 2. Thus, with two exceptions, affected
males with X-linked nephrolithiasis/Dent’s disease ex-from that in the adults with Dent’s disease (379 6 74
mg/day). The mean calcium excretion of the children creted extremely large quantities of both RBP and b2-
microglobulin, as reported previously [22, 23]. The twowith Dent’s disease (5.8 6 2.1 mg/kg/day) was somewhat
higher than for the children with IH (5.3 6 1.7 mg/kg/ exceptional individuals were patient V-4, who excreted
normal amounts of b2-microglobulin and RBP, and an-day), but this difference was not statistically significant
(P 5 0.42 by two-tailed t-test). other member of the large XRN kindred who shares the
Gly506Glu mutation but who is not hypercalciuric andMeasurements of parathyroid hormone (PTH) were
available in 43 of the subjects with IH (23 children and has no clinical abnormalities other than a modest eleva-
tion in excretion of LMW proteins. Carrier females ex-20 adults), and all were normal. Levels of 1,25-dihydroxy-
vitamin D were measured in 30 subjects (22 children and creted intermediate quantities of LMW proteins, and the
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Fig. 2. Excretion of retinol-binding protein (A, n) and b2-microglobulin (B, s) in affected males (AM) and carrier females (CF) with X-linked
nephrolithiasis/Dent’s disease, and adults and children with idiopathic hypercalciuria (IH) or normals (N). Each symbol represents the mean of
all measurements in a single patient, and the number of patients represented in each group is indicated below the axis. The horizontal lines
represent the established upper limit of normal for that measurement, and for retinol-binding protein (RBP), this value is different in adults and
children. The AM and CF groups each included several children.
separation among groups was most distinct for RBP. In tients with any abnormality in excretion of RBP or b2
contrast, excretion of RBP was normal in all but 9 of microglobulin, eight were available to provide blood
101 patients with IH. In those patients, RBP abnormali- samples, and direct sequencing was normal in all eight.
ties were slight; the highest of these abnormal values Direct sequencing of the 2238 base pair coding region
was 0.052 mg RBP/mmol creatinine. Similarly, urinary of the CLCN5 gene was identical in the GHS rat and
excretion of b2-microglobulin was normal in all hyper- the normal rat.
calciuric stone-forming patients except for one, whose
excretion of b2-microglobulin was only trivially abnor-
DISCUSSIONmal. In this patient, the excretion of RBP was at the
The observation of incidental hypercalciuria, withoutupper limit of normal (0.017 mg/mmol creatinine). Of
clinical disease, in an adult with an inactivating mutationthe nine patients with mild LMW proteinuria, three had
in the CLCN5 gene establishes that the range of pheno-excessive albumin excretion (.2.5 mg/mmol creatinine).
type associated with such mutations is very broad and
Screening for mutations in CLCN5 can encompass patients with hypercalciuria alone, even
in the absence of LMW proteinuria. The biochemicalThe CLCN5 gene was analyzed in a total of 32 patients
picture in this patient was indistinguishable from IH. Thus,with IH. An analysis of 312 SSCPs in 24 patients with IH
it was important to determine whether patients with hyper-chosen at random revealed no abnormal bands. SSCP
calciuria alone could harbor CLCN5 mutations. The pa-has been reported to have a reliability in detecting 80%
tients we studied were representative of patients withof CLCN5 mutations subsequently identified by direct
IH in general, with a tendency toward relatively low meansequencing in unselected patients [14]. These results of
serum phosphorus levels and relatively high levels ofSSCP analysis were confirmed by direct DNA sequenc-
ing in nine randomly selected patients. Of the nine pa- 1,25-dihydroxyvitamin D (1,25(OH)2D) (Table 1), and in
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this respect, they resemble patients with Dent’s disease this was a conservative single base change that did not
alter the amino acid sequence.[9]. The current study documents that CLCN5 mutations
In humans, the ClC-5 chloride channel is expressed inare not present in any significant percentage of the hyper-
the proximal tubule and the thick ascending limb ofcalciuric population. Assuming that direct sequencing
Henle’s loop [36]. Both are sites involved in calcium trans-(negative in 17 patients, including those with mild LMW
port, and the mechanism of hypercalciuria in Dent’s dis-proteinuria) has a sensitivity for CLCN5 mutations of
ease is currently unknown [10]. In the cells of the proxi-close to 100% and that SSCP (negative in an additional
mal tubule, ClC-5 colocalizes with the proton-ATPase15) has a sensitivity of 80% [14], it is likely that Dent’s
in the subapical endosomes and appears to be requireddisease could account for no more than 3% of patients
for acidification of the endosome that is an essential stepwith IH.
in degradation of reabsorbed proteins [28, 36]. Thus, inWith the sole exceptions of two mildly affected males
Dent’s disease, the LMW proteinuria, the most consis-(Fig. 2), all males with X-linked nephrolithiasis/Dent’s
tently observed clinical abnormality, is also the featuredisease with documented CLCN5 mutations have had
that is most clearly explained on the basis of currentdramatic degrees of LMW proteinuria, justifying the value
knowledge of ClC-5 expression.of this measurement as a screening test for this disease
Low molecular weight proteinuria is a nonspecific ab-[10, 23]. The mildest variant of this disease reported until
normality that occurs in a range of tubulointerstitial dis-now is the syndrome of LMW proteinuria with hypercal-
eases [37] and has been reported to occur in as many asciuria and nephrocalcinosis documented in several re-
13 to 17% of patients with stone disease [38, 39]. Thoseports in Japanese school children [12, 14, 19, 20, 24].
reports included patients with a variety of underlyingUrinary excretion of LMW proteins was normal in 92
causes of nephrolithiasis, and the authors speculated thatof 101 subjects with IH we tested. Only slight abnormali-
the LMW proteinuria reflected renal damage as a conse-ties in LMW protein excretion were found in the others,
quence of obstruction or infection. In our series, 9 of 101comparable to the lower rates of excretion among carrier
patients with IH had slight degrees of LMW proteinuria,females and two orders of magnitude lower than those
and the presence of albuminuria in two of these nine isof the typical affected male with Dent’s disease. No ab-
consistent with some degree of tubulointerstitial renalnormalities in the CLCN5 sequence were detected in
injury, despite normal creatinine clearance measure-these individuals with LMW proteinuria and IH.
ments. Furthermore, we have developed a quantitativeThe full clinical syndrome of Dent’s disease is charac-
definition of “tubular proteinuria” based on the LMWterized by proximal tubular solute wasting, proteinuria,
protein data in these patients with Dent’s disease [40].nephrocalcinosis, progressive renal insufficiency, and oc-
This definition relates the excretion of LMW proteins
casionally rickets or osteomalacia, in addition to hyper-
to that of albumin in order to account for the contribu-
calciuria and nephrolithiasis [10, 21–23]. Thus, the full tion of glomerular proteinuria to urinary protein excre-
syndrome includes findings clearly not found in uncom- tion [40]. Using this rigorous definition, only 2 of these
plicated IH. However, the expression of the Dent’s dis- 101 patients with IH have “tubular proteinuria.” A de-
ease phenotype can vary substantially even among indi- tailed characterization of LMW proteinuria in defined
viduals all of whom share the same CLCN5 mutation groups of patients with various conditions determined
[10]. Thus, for example, the S244L mutation is associated that the mild LMW proteinuria found in some of the
with severe rickets in male members of two families with patients with IH could be explained quantitatively by
“X-linked recessive hypophosphatemic rickets” [11, 16], hematuria [40].
but with significant renal failure and recurrent nephroli- The GHS rat model has been characterized extensively,
thiasis in the absence of rickets in other families [17, 18]. and many features of hypercalciuria in this rat resemble
A wide variation in phenotype within individual families metabolic patterns found commonly in humans with IH.
has also been described [10, 22]. The two male patients For example, exaggerated intestinal calcium absorption
described here with a CLCN5 mutation but very mild plays a prominent role in these rats [41], and there are also
clinical abnormalities further reinforce this point, as contributions of impaired renal calcium transport [42] and
other males in this family who share the same mutation enhanced resorption of bone mineral [27]. GHS rats have
have had severe abnormalities, including end-stage renal normal blood levels of 1,25-(OH)2D but overexpression
failure and recurrent nephrolithiasis. of the vitamin D-receptor in target tissues [43], whereas
In polygenic conditions, the phenotype can reflect the patients with X-linked nephrolithiasis/Dent’s disease
effects of common polymorphisms in multiple genes. tend to have mild elevations in serum 1,25-(OH)2D lev-
However, our studies by direct sequencing and SSCP els, as do some patients with IH. Nevertheless, it is likely
revealed no polymorphisms in the CLCN5 sequence in that several genes contribute to hypercalciuria in the
the 32 hypercalciuric patients studied. To date, only one GHS rat, although this study establishes that the coding
sequence of CLCN5 is not mutated in this rat model.polymorphism has been reported in this gene [14], and
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